000 01370 a2200349 4500
005 20250516080225.0
264 0 _c20120523
008 201205s 0 0 eng d
022 _a1469-493X
024 7 _a10.1002/14651858.CD007743.pub3
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aRobinson, Karen A
245 0 0 _aPalivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
_h[electronic resource]
260 _bThe Cochrane database of systematic reviews
_cFeb 2012
300 _aCD007743 p.
_bdigital
500 _aPublication Type: Journal Article; Review; Systematic Review
650 0 4 _aAntibodies, Monoclonal, Humanized
_xadverse effects
650 0 4 _aAntiviral Agents
_xadverse effects
650 0 4 _aCystic Fibrosis
_xcomplications
650 0 4 _aHumans
650 0 4 _aInfant
650 0 4 _aPalivizumab
650 0 4 _aPseudomonas Infections
_xepidemiology
650 0 4 _aPseudomonas aeruginosa
650 0 4 _aRandomized Controlled Trials as Topic
650 0 4 _aRespiratory Syncytial Virus Infections
_xdrug therapy
700 1 _aOdelola, Olaide A
700 1 _aSaldanha, Ian J
700 1 _aMcKoy, Naomi A
773 0 _tThe Cochrane database of systematic reviews
_gno. 2
_gp. CD007743
856 4 0 _uhttps://doi.org/10.1002/14651858.CD007743.pub3
_zAvailable from publisher's website
999 _c21547492
_d21547492